Table 4. Repurposable drugs based on Connectivity Map.
List of repurposable drugs based on connectivity map analysis using CLUE. Drugs with known anti-viral activity is highlighted in bold characters.
| Sl. No. | Id | Name* | Description | Target | tau score | Drug bank id | Therapy area | Drug group | Anti-viral activity (PUBMED id) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BRD-K11853856 | PJ-34 | PARP inhibitor | EEF2, PARP1, PARP15, PARP3 | −99.93 | anticancer drugs | |||
| 2 | BRD-K40887525 | Ritanserin | serotonin receptor antagonist | HTR2A, HTR2C, HTR2B, ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR5A, HTR6, HTR7 | −99.89 | DB12693 | clinical trials for schizophrenia and migraine. | Investigational | 19703243 |
| 3 | BRD-K72541103 | JAK3-inhibitor-I | JAK inhibitor | JAK3 | −99.89 | 22359619 | |||
| 4 | BRD-A37959677 | Estrone | estrogen receptor agonist, estrogenic hormone | ESR1, ESR2 | −99.86 | DB00655 | menopausal hormone therapy | Approved | |
| 5 | BRD-K63195589 | Tipifarnib | farnesyltransferase inhibitor, angiogenesis inhibitor, apoptosis stimulant | FNTA, FNTB | −99.86 | DB04960 | cancer | Investigational | 28677645 |
| 6 | BRD-K78084463 | W-12 | calmodulin antagonist | −99.82 | Cardiac dysrhythmias | unknown | 27940224 | ||
| 7 | BRD-K52640952 | BRD-K52640952 | topoisomerase inhibitor | TOP1 | −99.72 | 1707642 | |||
| 8 | BRD-K99946902 | hexylresorcinol | polyphenol oxidase inhibitor | TYR | −99.61 | DB11254 | antiseptic, anthelmintic, and local anesthetic properties | Approved | 26408353 |
| 9 | BRD-K64451768 | GANT-58 | GLI antagonist | DHH, GLI1, IHH | −99.61 | ||||
| 10 | BRD-K22385716 | LY-303511 | casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor | CSNK2A1, CSNK2A2, CSNK2B, MTOR | −99.54 | 29369973, 30405592, 26388843 | |||
| 11 | BRD-K10065684 | Dantron | stimulant laxative | −99.51 | DB04816 | Drugs for Constipation | Approved, Investigational, Withdrawn | ||
| 12 | BRD-A44448661 | Pentobarbital | GABA receptor modulator | GABRA1, CHRNA4, CHRNA7, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B | −99.44 | DB00312 (APRD01174) | anti-anxiety agent | Approved, Investigational, Vet approved | |
| 13 | BRD-K98143437 | SB-239063 | p38 MAPK inhibitor, interleukin inhibitor, tumor necrosis factor production inhibitor | MAPK11, MAPK14, PTGS2, TNF | −99.44 | 11046054 | |||
| 14 | BRD-K91904471 | SD-169 | p38 MAPK inhibitor | MAPK14 | −99.37 | 11046054 | |||
| 15 | BRD-K43149758 | Myricetin | androgen receptor ligand, cytochrome P450 inhibitor | PIK3CG, AR, CYP3A4 | −99.37 | DB02375 (EXPT02265) | antioxidant properties | Experimental | |
| 16 | BRD-A02006392 | Nitrendipine | calcium channel blocker, L-type calcium channel blocker | CACNA1C, CACNA1D, CACNA2D1, CACNA1H, CACNA1S, CACNA2D2, CACNB2, CACNG1, KCNN4 | −99.35 | DB01054 (APRD00421) | antihypertensive agent | Approved, Investigational | |
| 17 | BRD-A59808129 | Guggulsterone | estrogen receptor agonist, FXR antagonist, progesterone receptor agonist, cholesterol inhibitor, IKK inhibitor, PXR agonist | NR1H4, PGR, AR, ESR1, IKBKB, NR1I2, NR3C1, NR3C2 | −99.33 | endocrinology | pre-clinical | ||
| 18 | BRD-K76304753 | phenazopyridine | unidentified pharmacological activity | SCN1A | −99.22 | DB01438 | analgesic effect | Approved | |
| 19 | BRD-A77050075 | heraclenol (Cobamamide) | furocoumarin compound with antiproliferative activity at G2/M phase | −99.22 | DB11191 | Neurological | Approved | 347911148 | |
| 20 | BRD-K32398298 | Alprazolam | GABA benzodiazepine site receptor agonist, benzodiazepine receptor agonist | GABRA1, GABRA2, GABRA3, GABRA5, CYP3A5, GABRA4, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ | −99.22 | DB00404 (APRD00280, DB05925, DB05690) | Approved, Illicit, Investigational | 8255908 | |
| 21 | BRD-K48722258 | Dilazep | adenosine reuptake inhibitor, calcium channel antagonist, platelet aggregation inhibitor | SLC29A1, CACNA1C | −99.19 | DB13715 | cardiovascular agents | Experimental | 25091947 |
| 22 | BRD-K30351863 | BRD-K30351863 | APEX inhibitor | APEX1 | −99.19 | ||||
| 23 | BRD-K17823458 | Danoprevir | HCV inhibitor, serine protease inhibitor | −99.15 | DB11779 (DB06038) | protease inhibitor | Investigational | 24295986 | |
| 24 | BRD-A60274948 | Bromocriptine | dopamine receptor agonist, dopamine receptor antagonist, prolactin secretion inhibitor | DRD2, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, ADRA1A, ADRA1B, ADRA1D, HTR6, HTR7, PRL | −99.08 | DB01200 (APRD00622) | dopaminergic activity | Approved, Investigational | |
| 25 | BRD-K90382497 | GW-843682X | PLK inhibitor | PLK1, PLK3 | −99.05 | ||||
| 26 | BRD-K74761218 | WT-171 (Vorinostat) | HDAC inhibitor | HDAC6 | −99.01 | DB02546 (EXPT02902) | anti-coagulant activity | Approved, Investigational | 5311 |
| 27 | BRD-K14880289 | GW-501516 (Cardarine) | PPAR receptor agonist, insulin sensitizer | PPARD, INS, PPARA | −99.01 | DB05416 (DB13015) | cardiovascular | Investigational | 9803963 |